Uniportal robotic-assisted thoracic surgery (U-RATS) represents a recent evolution in minimally invasive lung resection, combining the single-incision philosophy with robotic technology. However, its perioperative safety and outcomes have not been clearly defined across published studies. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and a registered protocol. PubMed, Web of Science, and the Cochrane Library were searched for studies reporting perioperative outcomes of U-RATS for anatomic lung resection in adults. Primary outcomes included conversion rate, morbidity, and mortality. Secondary outcomes were operative time, estimated blood loss, length of hospital stay, and lymph node yield. Random-effects models were applied to pool estimates. Sixteen studies encompassing 579 patients were included. The pooled conversion rate was 1.34% (95% CI: 0.42–4.15%), with no observed heterogeneity. The pooled postoperative morbidity rate was 5.99% (95% CI: 4.46–7.91%), and the pooled mortality rate was 0.21% (95% CI: 0.07–0.64%). The pooled mean operative time was 171.3 min, the estimated blood loss was 51.9 mL, and the postoperative length of stay was 4.9 days. Across 11 studies, the pooled lymph node yield was 16.6 nodes (95% CI: 14.0–19.2; I² = 89.8%). Current evidence suggests that U-RATS is a safe and feasible approach for anatomic lung resection, with low conversion and complication rates and acceptable perioperative outcomes comparable to established minimally invasive techniques.
Adhesive small bowel obstruction (aSBO) is a common cause of emergency surgical admission, and the optimal initial management between early surgery and conservative non-operative management (NOM) remains debated, particularly regarding recurrence and short-term safety. This systematic review aimed to evaluate short- and long-term outcomes of early operative management compared with conservative treatment for aSBO in adult and paediatric populations. A systematic search of MEDLINE, Embase, Scopus, and Cochrane CENTRAL was conducted from inception to 2025 in accordance with PRISMA guidelines. Nine studies were included. In stable adults, NOM was generally safe with comparable short-term complication and mortality rates to early surgery; however, prolonged delays following NOM failure were associated with increased morbidity and bowel resection. Long-term outcomes consistently favoured early operative management, demonstrating a 40-60% relative reduction in recurrence. Water-soluble contrast protocols improved diagnostic accuracy and NOM success, while specific radiological findings predicted failure. In paediatric patients, NOM was effective in many cases, but infants under one year of age had a higher likelihood of requiring surgery, and delays beyond 48 hours increased bowel resection rates. Overall, NOM is safe for selected patients, but early surgery offers superior long-term recurrence outcomes.
adhesive small bowel obstructionearly surgical interventionconservative treatmentrecurrence
International Journal of Analytical Chemistry · مجلد 2026 (1) · 4376722-4376722
Dasatinib, a therapy for chronic myeloid leukemia, suffers from poor bioavailability. Self‐microemulsifying drug delivery systems (SMEDDSs) are used to improve its dissolution. This study aimed to develop and validate a novel reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method for quantifying dasatinib in SMEDDS formulations. The RP‐HPLC method utilized a mobile phase of methanol and 0.1% trifluoroacetic acid (55:45, v/v) and identified a peak wavelength for dasatinib at 324 nm. SMEDDS formulations comprised Capryol 90, Transcutol HP, and Tween 40. The method was validated according to ICH guidelines, demonstrating excellent linearity ( R 2 = 0.9993), accuracy (recovery between 98% and 101%), and precision (relative standard deviation of 0.73%). It also showed stability and reliability with limits of detection and quantification of 0.17 and 0.50 µg/mL, respectively. This RP‐HPLC method meets all validation criteria and provides a robust, cost‐effective tool for analyzing dasatinib in SMEDDS formulations.
dasatinibself-microemulsifying drug delivery systemRP-HPLC method developmentmethod validation
INQUIRY The Journal of Health Care Organization Provision and Financing · مجلد 63 · 469580251405998-469580251405998
Teledermatology has become an important tool for expanding access to dermatologic care, especially in geographically large countries such as Saudi Arabia. Saudi Arabia's digital transformation and the shortage of dermatologists in rural regions have created favorable conditions for the adoption of teledermatology. Several platforms now provide virtual dermatology consultations. This narrative review aimed to explore teledermatology's current status, acceptance, barriers, and future directions in Saudi Arabia. The literature indicates that both dermatologists and patients are generally receptive to teledermatology, particularly for follow-up care; however, concerns about the lack of physical examination and reduced interpersonal interaction persist. A SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis revealed that Saudi Arabia's strong digital infrastructure, high smartphone penetration, and alignment with Vision 2030 are major strengths supporting teledermatology expansion. Key weaknesses include regulatory and reimbursement gaps, limited digital literacy, and the lack of dermatology-specific guidelines. Opportunities lie in extending services to underserved areas and integrating artificial intelligence, whereas threats include cultural resistance, cybersecurity risks, and potential inequities in digital access. In conclusion, teledermatology in Saudi Arabia is rapidly developing and shows considerable promise; however, its sustainability will depend on targeted investment, regulatory reforms, and efforts to promote equitable access.
teledermatologySaudi Arabiaaccess to dermatologic caretelehealth adoption barriers
Fibromyalgia causes symptoms like chronic widespread pain, fatigue, and cognitive difficulties, often alongside depression and chronic pain, complicating treatment. While selective serotonin reuptake inhibitors (SSRIs) are prescribed for fibromyalgia-related depression and pain, their effectiveness is unclear. This systematic review and meta-analysis evaluated SSRI efficacy in fibromyalgia patients with comorbid depression and chronic pain. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid, and Google Scholar. We included randomized controlled trials (RCTs) using formal fibromyalgia criteria and reporting depression or pain outcomes. Non-RCTs, studies with non-adults, or non-SSRI comparisons without isolating SSRI effects were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB-2) was used to assess the risk of bias in this study. Four reviewers independently screened titles and abstracts; four assessed full-texts with disagreements resolved by a senior reviewer. Outcome data were converted to mean change scores from baseline where not directly reported. The standardized mean difference (SMD) was used for the meta-analysis to pool data across different scales. Nine RCTs (n = 461 participants, predominantly female, mean ages across studies ranged from 32.7 to 52.9 years) were analyzed. Compared to placebo, SSRIs significantly reduced pain (eight RCTs, n = 421; SMD -0.53, 95% confidence interval (CI): -0.92 to -0.14, p = 0.007) and improved depression (six RCTs, n = 265; SMD -0.67, 95% CI: -1.14 to -0.20, p = 0.005). SSRIs also significantly improved quality of life (QOL) versus placebo (five RCTs, n = 301; SMD -0.30, 95% CI: -0.55 to -0.04, p = 0.02). Compared to other non-pharmacological interventions (acupuncture and aerobic exercise), SSRIs showed non-significant improvement in depression (two RCTs, n = 70; SMD -0.39, 95% CI: -1.32 to 0.54, p = 0.41). Common side effects included gastrointestinal issues, dry mouth, sedation, sexual dysfunction, and headaches; SSRI groups reported more adverse events and higher dropout rates. SSRIs showed statistically significant benefits for pain, depression, and QOL in fibromyalgia compared to placebo. However, the overall evidence quality was found to be very low to low due to heterogeneity and risk of bias. Future RCT designs should adhere to a strict methodology in order to strengthen the available evidence on the efficacy of SSRIs in treating fibromyalgia.
Avicenna Journal of Medicine · مجلد 16 (01) · 004-015
Globally, 1 in 10 children are impacted by war, with over 24,000 violations documented in 2020 alone. These children face persistent mental health challenges, including anxiety, depression, and posttraumatic stress disorder (PTSD). This systematic review evaluates current psychological interventions for war-affected children. Following PRISMA guidelines, 10 studies (2013-2021) from conflict zones in non-high-income countries were analyzed. Clinical interventions such as the Teaching Recovery Techniques (TRTs) are crucial; TRT is a low-cost intervention implementable by trained nonprofessionals under supervision. Findings revealed that TRT showed promise, especially when combined with parenting sessions, underscoring the importance of caregiver involvement. School-based programs were effective in addressing PTSD and anxiety symptoms, highlighting the key role of schools and trained teachers. Reading interventions improved affect recognition, and life-skills approaches enhanced social coping, but the most impactful strategies integrated caregivers. Successful interventions combined parental and community support, emphasizing cultural adaptation and individualized approaches for sustained mental health improvements.
war-affected childrenchild and adolescent mental healthpsychological interventionpost-traumatic stress disorder
Background/Objectives: Children with Down syndrome are at increased risk of obstructive sleep apnea (OSA), which cannot be reliably excluded by symptoms or examination. Saudi evidence remains limited. This review synthesizes international and Saudi evidence and proposes a pediatric care pathway incorporating the transition to adult services. Methods: We conducted a structured narrative review of the English-language literature identified through PubMed/MEDLINE, selected journal websites, and reference lists. The review focused on publications from January 2018 to 17 September 2026, retaining relevant earlier studies. Evidence was synthesized qualitatively without a new meta-analysis or formal risk of bias assessment. Results: Published international estimates indicate that OSA affects approximately 50–79% of children with Down syndrome. American Academy of Pediatrics guidance recommends polysomnography (PSG) at ages 3–4 years regardless of symptoms, with earlier assessment when indicated. Nonrandomized infant intervention studies suggest potential benefits but do not establish an optimal universal screening schedule. Saudi evidence includes a small earlier PSG referral cohort and more recent caregiver surveys; no nationally representative PSG-confirmed prevalence study was identified. Arabic questionnaire validation in a mixed pediatric referral cohort does not establish Down syndrome-specific diagnostic accuracy. Published treatment evidence indicates that adenotonsillectomy often improves OSA, although residual disease commonly requires objective reassessment and individualized management. Conclusions: The evidence supports age-based PSG, earlier assessment when indicated, postoperative reassessment, and individualized multidisciplinary care. Building on this evidence, we propose a Saudi pathway linking referral tracking, family-centered positive airway pressure support, and coordinated transition. Regional networks and registry development remain unevaluated implementation proposals requiring stakeholder consultation, resource assessment, and pilot testing; they do not constitute an endorsed national guideline.
Down syndromeobstructive sleep apneasleep-disordered breathingpolysomnography screening
Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.
Journal of Clinical Medicine · مجلد 15 (18) · 7071-7071
Background/Objectives: To systematically evaluate and compare the clinical efficacy and safety of non-cryotherapy modalities versus standard liquid nitrogen cryotherapy for the treatment of plantar warts, while exploring the influence of specific cryotherapy procedural parameters and intervention-related subgroup characteristics on treatment outcomes. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA guidelines. We searched four major databases from inception until 1 July 2026. The primary outcome was complete clearance. Secondary outcomes included partial clearance, recurrence, and treatment-related adverse events. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models. Results: Thirty-one RCTs involving 2313 patients were included. No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy in complete clearance rates (RR = 1.09, 95% CI: 0.98–1.20; p = 0.10; I2 = 0.00%) or recurrence outcomes (RR = 0.90, 95% CI: 0.56–1.44; p = 0.66). Partial clearance significantly favored cryotherapy (RR = 0.65, 95% CI: 0.44–0.95; p = 0.03), particularly in subgroup analyses using two freeze–thaw cycles and treatment intervals of every two weeks. Regarding safety, topical therapies demonstrated significantly lower erythema rates than cryotherapy, while no statistically significant differences were observed in blistering, scarring, or secondary bacterial infection. Conclusions: No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy regarding complete clearance or recurrence of plantar warts. Cryotherapy may offer better partial clearance under optimized treatment parameters, whereas topical therapies may be better tolerated in selected patients.
Background: Scapular-targeted rehabilitation is increasingly incorporated into the management of rotator cuff-related shoulder disorders; however, its clinical value across both conservative and postoperative stages of care remains uncertain. Objective: To evaluate the effectiveness of scapular-targeted rehabilitation on pain, disability, and shoulder function across the rotator cuff care continuum. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through May 2026. Eligible studies included adults with rotator cuff-related shoulder pain, subacromial pain syndrome, subacromial impingement syndrome, scapular dyskinesis-associated shoulder disorders, or patients undergoing rehabilitation following rotator cuff repair. Randomized controlled trials were included in quantitative synthesis. Random-effects models were used to pool standardized mean differences (SMDs) or mean differences (MDs) with 95% confidence intervals (CIs). Results: Nine studies met the inclusion criteria, comprising seven randomized controlled trials, one propensity score-matched study, and one single-group pre-post study. Meta-analysis demonstrated that scapular-targeted rehabilitation significantly reduced pain compared with control interventions (SMD -0.88, 95% CI -1.71 to -0.06; I²=84.8%) and significantly improved shoulder function measured by the Constant-Murley Score (MD 6.94, 95% CI 0.37 to 13.52; I²=85.7%). Disability outcomes favored scapular-targeted rehabilitation but did not reach statistical significance (SMD -0.47, 95% CI -1.05 to 0.11; I²=72.8%). Postoperative studies generally reported favorable effects on pain, function, and range of motion, although evidence was insufficient for quantitative synthesis. Conclusions: Scapular-targeted rehabilitation appears to be a useful adjunct within comprehensive rotator cuff rehabilitation, with evidence supporting improvements in pain and shoulder function. Evidence for disability reduction and postoperative effectiveness remains inconclusive, warranting further high-quality trials across the rotator cuff care continuum.
American Journal of Pediatrics · مجلد 12 (3) · 87-102
Background: Parapneumonic effusion (PPE) and empyema remain serious complications of childhood pneumonia associated with significant morbidity despite advances in antimicrobial therapy and surgical techniques. Accurate disease staging and timely stage-directed intervention are fundamental to optimal outcomes. Objective: To provide a current, evidence-based synthesis of the definition, etiology, diagnosis, and management of complicated pneumonia in children, with particular focus on areas of ongoing clinical controversy. Methods: A narrative review incorporating randomized controlled trials, systematic reviews, meta-analyses, Cochrane reviews, and international clinical guidelines published between 2016 and 2026 was conducted. PubMed was searched through May 2026 using terms including pneumonia, complicated pneumonia, parapneumonic effusion, empyema, VATS, fibrinolysis, decortication, and pediatric. Results: Chest radiography remains the initial imaging modality for suspected complicated pneumonia, with lateral decubitus views needed to assess pleural fluid mobility. However, chest ultrasonography is the preferred imaging modality for evaluating parapneumonic effusions and empyema because of its superior diagnostic accuracy, ability to characterize pleural collections, and absence of ionizing radiation. Management is stage-dependent, combining targeted antibiotic therapy with procedural intervention when indicated. Image-guided pigtail catheter drainage with intrapleural fibrinolytic therapy is effective for most patients. VATS demonstrates particular utility during the fibrinopurulent stage. No single fibrinolytic agent has demonstrated clear superiority; however, tissue plasminogen activator is most widely employed. Open decortication remains reserved for refractory or advanced-stage disease. Conclusion: Early diagnosis, appropriate antibiotics, and prompt intervention or surgery are all important for optimal care. The optimal outcomes require a multidisciplinary, individualized, stage-directed approach. Interventional radiology is appropriate for single loculations, while early VATS is favored for thick pleural rind or multiple loculations. Further high-quality prospective research is needed to establish definitive treatment algorithms.
International Journal of Emergency Medicine · مجلد 19 (1)
INTRODUCTION: First responders, including Emergency Medical Services (EMS) personnel, police officers, firefighters, and disaster responders, are at increased risk of developing post-traumatic stress disorder (PTSD) due to repeated exposure to traumatic events. Although EMS personnel face unique occupational stressors, much of the available evidence on PTSD interventions is derived from broader first-responder populations. This study aimed to synthesize evidence on the effectiveness, feasibility, and sustainability of psychological interventions for PTSD among first responders, with particular attention to their relevance for EMS personnel. METHODS: A systematic review was conducted following PRISMA guidelines. Randomized controlled trials and quasi-experimental studies were included. Eligible studies involved first responders, including EMS personnel, police officers, firefighters, disaster workers, and emergency service personnel. Psychological interventions analyzed included trauma-focused therapies (e.g., eye movement desensitization and reprocessing [EMDR] and cognitive behavioral therapy [CBT]), group-based approaches (e.g., critical incident stress debriefing [CISD]), and resilience- or mindfulness-based programs. Primary outcomes were PTSD symptoms measured using validated instruments, while secondary outcomes included psychological distress, resilience, and related mental health indicators. RESULTS: Fifteen studies with varying sample sizes were included. Trauma-focused interventions, particularly EMDR and CBT, demonstrated the most consistent effectiveness in reducing PTSD symptoms across first-responder populations. Group-based interventions showed mixed findings, with some studies reporting short-term benefits and others demonstrating limited or no effect on PTSD outcomes. Resilience- and mindfulness-based programs were generally associated with improvements in short-term psychological well-being but showed limited evidence of sustained long-term benefits. Seven studies were assessed as having a low risk of bias, while the remaining studies presented methodological limitations of varying severity. CONCLUSIONS: EMDR and CBT appear to be the most promising interventions for reducing PTSD symptoms among first responders. However, the evidence specific to EMS personnel remains limited, as many available studies involve broader first-responder populations. Further high-quality, EMS-specific research with standardized outcome measures and long-term follow-up is needed to strengthen the evidence base and inform occupational mental health practice.
post-traumatic stress disorderfirst respondersemergency medical personnelpsychological intervention
Objective: To evaluate and compare the safety and effectiveness of antipsychotic medications for the treatment of hiccups, thereby guiding clinicians toward evidence-based treatment guidelines. Hiccups are often benign and self-limiting; however, they can become persistent and intractable, adversely affecting the quality of life. Antipsychotics have been identified as a therapeutic option for the management of hiccups; however, the available evidence supporting their safety and efficacy has not been synthesized. Methods: This review utilized the revised Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Cochrane Risk of Bias Assessment Tool was modified to evaluate the quality of the selected studies. The search strategy included terms related to or describing hiccups and antipsychotics. Research articles in English published between 1974 and March 2024 were searched in different databases. Duplicates and eligibility criteria were used to screen articles. Results: A search of Medline, Scopus, and Web of Science yielded 1537 articles, of which 1042 were retained after removing duplicates, and 16 met the inclusion criteria. The studies that met the inclusion criteria were all case reports, case series, or retrospective studies, with no randomized trials. A few antipsychotics have been shown to totally or partially alleviate hiccups. Nine studies reported that hiccups were completely resolved in patients treated with 10-25 mg oral and intramuscular chlorpromazine, 1-2 mg oral and intramuscular haloperidol, 2.5-10 mg oral olanzapine, 25-150 mg tetrabenazine, and 3 mg oral risperidone. Adverse events were documented in 7 of the studies. Conclusion: Chlorpromazine and olanzapine are effective antipsychotics for hiccup treatment. However, more evidence-based studies and controlled clinical trials are needed to confirm the efficacy and minimize the side effects. PROSPERO registration: (CRD42024511626).
BackgroundThe emergency medical services (EMS) sector presents substantial hurdles in providing excellent treatment while operating within limited resources. Artificial intelligence (AI) has significant potential in prehospital EMS, where rapid and accurate decision-making is essential. However, a comprehensive synthesis of AI’s effectiveness in this setting remains limited. The objective of this systematic review and meta-analysis was to evaluate AI’s predictive accuracy, compare its performance with human-based triage, and assess its feasibility in prehospital care. MethodsFollowing PRISMA guidelines, PubMed, Cochrane Library, and Web of Science were searched up to February 20, 2025. Fourteen peer-reviewed studies reporting quantitative outcomes were included. Study quality was assessed using the Newcastle-Ottawa Scale (median score = 7). Random-effects meta-analyses in R were conducted to synthesize area under the curve (AUC), AI-human AUC differences, and feasibility outcomes. ResultsAcross 14 studies involving 9,107,906 patients, AI demonstrated strong predictive performance with a pooled AUC of 0.874 (95% CI: 0.843–0.905). Individual study AUCs ranged from 0.805 to 0.997, with moderate heterogeneity (I²=52.3%). In eight studies, AI significantly outperformed human triage, showing a pooled AUC improvement of 0.074 (95% CI: 0.045–0.103; p<0.001), despite high heterogeneity due to varying human benchmarks. Feasibility analysis showed high clinical utility, with a pooled proportion of 0.929 and no heterogeneity (I²=0%). Funnel plots suggested slight asymmetry, but Egger’s tests indicated no significant publication bias. ConclusionArtificial intelligence demonstrated high predictive accuracy, slight superiority over human triage, and strong feasibility in prehospital care, supporting its integration into EMS with further validation and standardized reporting.
artificial intelligenceprehospital emergency medical servicesemergency medical triageprediction accuracy